Cho et al. “4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6.” Journal of Medicinal Chemistry 53, no. 22 2010: 7938–7957. DOI: 10.1021/jm100571n.

/in ,

Cho et al. “4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6.” Journal of Medicinal Chemistry 53, no. 22 2010: 7938–7957. DOI: 10.1021/jm100571n.

Christopher W. Murray and Tom L. Blundell. “Structural Biology in Fragment-Based Drug Design.” Current Opinion in Structural Biology 20, no. 4 2010: 497-507. DOI: 10.1016/j.sbi.2010.04.003.

/in ,

Christopher W. Murray and Tom L. Blundell. “Structural Biology in Fragment-Based Drug Design.” Current Opinion in Structural Biology 20, no. 4 2010: 497-507. DOI: 10.1016/j.sbi.2010.04.003.

Dawson M. A. et al. “AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.” British Journal of Haematology 150, no. 1 2010: 46-57. DOI: 10.1111/j.1365-2141.2010.08175.x.

/in ,

Dawson M. A. et al. “AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.” British Journal of Haematology 150, no. 1 2010: 46-57. DOI: 10.1111/j.1365-2141.2010.08175.x.

McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.

/in ,

McHardy et al. “Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt).” Journal of Medicinal Chemistry 53, no. 5 2010: 2239–2249. DOI: 10.1021/jm901788j.

Murray et al. “Fragment-Based Drug Discovery Applied to HSP90. Discovery of Two Lead Series with High Ligand Efficiency.” Journal of Medicinal Chemistry 53, no. 16 2010: 5942–5955. DOI: 10.1021/jm100059d.

/in ,

Murray et al. “Fragment-Based Drug Discovery Applied to HSP90. Discovery of Two Lead Series with High Ligand Efficiency.” Journal of Medicinal Chemistry 53, no. 16 2010: 5942–5955. DOI: 10.1021/jm100059d.

Santo et al. “AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.” Oncogene 29, no. 16 2010: 2325-2336. DOI: 10.1038/onc.2009.510.

/in ,

Santo et al. “AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.” Oncogene 29, no. 16 2010: 2325-2336. DOI: 10.1038/onc.2009.510.

Squires M. et al. “AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples.” Molecular Cancer Therapeutics 9, no. 4 2010: 920-928. DOI: 10.1158/1535-7163.MCT-09-1071.

/in ,

Squires M. et al. “AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples.” Molecular Cancer Therapeutics 9, no. 4 2010: 920-928. DOI: 10.1158/1535-7163.MCT-09-1071.

Tanaka et al. “Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells.” Blood 116, no. 12 2010: 2089-2095. DOI: 10.1182/blood-2009-03-211466.

/in ,

Tanaka et al. “Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells.” Blood 116, no. 12 2010: 2089-2095. DOI: 10.1182/blood-2009-03-211466.

Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b.

/in ,

Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b.